- £1.26bn
- £863.10m
- £4.12bn
- 97
- 83
- 93
- 100
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.72 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -0.8% | ||
| Dividend Yield (f) | 4.59% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.16 | ||
| Price to Tang. Book | 3.52 | ||
| Price to Free Cashflow | 6.78 | ||
| Price to Sales | 0.3 | ||
| EV to EBITDA | 5.47 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.01% | ||
| Return on Equity | 22.12% | ||
| Operating Margin | 3.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 3,071.3 | 3,034 | 3,212.8 | 3,612.2 | 4,117.7 | 4,317.15 | 4,431.48 | 6.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +2.14 | -36.56 | +118.6 | -5.22 | +32.9 | -7.96 | +7.74 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Morgan Sindall Group plc is a United Kingdom-based construction and regeneration company. The Company has six divisions: Construction, Infrastructure, Fit Out, Property Services, Partnership Housing and Urban Regeneration. Construction division is focused on the education, healthcare, commercial, industrial, leisure and retail markets. Infrastructure division is focused on highways, rail, energy, water and nuclear markets. Fit Out division is specialized in fit out and refurbishment in commercial, central and local government offices, retail banking and further education. The division also provides office interior design and build services direct to occupiers. Property Services division provides response and planned maintenance for social housing and the wider public sector. Partnership Housing division delivers housing through mixed-tenure and contracting activities. Urban Regeneration division works with landowners and public sector partners to transform the urban landscape.
Directors
- Michael Findlay NEC
- John Morgan CEO
- Stephen Crummett FID
- Chris Booth MDR
- Pat Boyle MDR
- Steve Coleby MDR
- Matthew Crompton MDR
- Alan Hayward MDR
- Martin Lubieniecki MDR
- Simon Smith MDR
- Andy Saul OTH
- Clare Sheridan SEC
- Kathy Quashie NED
- Malcolm Cooper NID
- Tracey Killen NID
- David Lowden NID
- Jennifer Tippin NID
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 20th, 1953
- Public Since
- January 3rd, 1986
- No. of Shareholders
- 2,084
- No. of Employees
- 7,689
- Sector
- Construction & Engineering
- Industry
- Industrials
- Exchange
London Stock Exchange- Shares in Issue
- 47,364,160
- Address
- Kent House, 14-17 Market Place, LONDON, W1W 8AJ
- Web
- https://www.morgansindall.com/
- Phone
- +44 2073079200
- Auditors
- Ernst & Young LLP
Latest News for MGNS
Upcoming Events for MGNS
Half Year 2024 Morgan Sindall Group PLC Earnings Release
Similar to MGNS
Alumasc
London Stock Exchange
Aukett Swanke
London Stock Exchange
Balfour Beatty
London Stock Exchange
Billington Holdings
London Stock Exchange
Henry Boot
London Stock Exchange
FAQ
As of Today at 22:09 UTC, shares in Morgan Sindall are trading at 2,595.00p. This share price information is delayed by 15 minutes.
Shares in Morgan Sindall last closed at 2,595.00p and the price had moved by +46.78% over the past 365 days. In terms of relative price strength the Morgan Sindall share price has outperformed the FTSE All Share Index by +32.48% over the past year.
The overall consensus recommendation for Morgan Sindall is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Morgan Sindall dividend yield is 4.39% based on the trailing twelve month period.
Last year, Morgan Sindall paid a total dividend of £1.14, and it currently has a trailing dividend yield of 4.39%. We do not have any data on when Morgan Sindall is to next pay dividends.
We do not have data on when Morgan Sindall is to next pay dividends. The historic dividend yield on Morgan Sindall shares is currently 4.39%.
To buy shares in Morgan Sindall you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 2,595.00p, shares in Morgan Sindall had a market capitalisation of £1.23bn.
Here are the trading details for Morgan Sindall:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: MGNS
Based on an overall assessment of its quality, value and momentum Morgan Sindall is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Morgan Sindall is 2,751.67p. That is 6.04% above the last closing price of 2,595.00p.
Analysts covering Morgan Sindall currently have a consensus Earnings Per Share (EPS) forecast of £2.33 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Morgan Sindall. Over the past six months, its share price has outperformed the FTSE All Share Index by +8.61%.
As of the last closing price of 2,595.00p, shares in Morgan Sindall were trading +17.58% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Morgan Sindall PE ratio based on its reported earnings over the past 12 months is 10.72. The shares last closed at 2,595.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Morgan Sindall's management team is headed by:
- Michael Findlay - NEC
- John Morgan - CEO
- Stephen Crummett - FID
- Chris Booth - MDR
- Pat Boyle - MDR
- Steve Coleby - MDR
- Matthew Crompton - MDR
- Alan Hayward - MDR
- Martin Lubieniecki - MDR
- Simon Smith - MDR
- Andy Saul - OTH
- Clare Sheridan - SEC
- Kathy Quashie - NED
- Malcolm Cooper - NID
- Tracey Killen - NID
- David Lowden - NID
- Jennifer Tippin - NID